Search / Trial NCT00002226

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

Launched by SUGEN · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Skin Neoplasms Sarcoma, Kaposi Antineoplastic Agents

ClinConnect Summary

Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • Are at least 18 years old.
  • Are HIV-positive.
  • Have KS with at least 5 skin lesions.
  • Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
  • Agree to use effective methods of birth control during the study.
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • Have had surgery within 4 weeks of study entry.
  • Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
  • Have pulmonary KS (KS in your lungs).
  • Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
  • Are allergic to Cremophor.
  • Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
  • Are pregnant.

About Sugen

Suggen is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of complex diseases. With a strong emphasis on research and development, Suggen focuses on harnessing cutting-edge science to create effective solutions that improve patient outcomes. The company collaborates with leading academic institutions and healthcare professionals to conduct rigorous clinical trials, ensuring the highest standards of safety and efficacy. Committed to transparency and ethical practices, Suggen aims to address unmet medical needs and elevate the standard of care through its groundbreaking therapeutic advancements.

Locations

New York, New York, United States

Los Angeles, California, United States

Los Angeles, California, United States

San Francisco, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials